 |
|
 |
Company Information |
|
|
Premium Company Profile - ViroPharma
Strategy, SWOT Analysis and 5-year Financial Insights with In-depth Company Profile
Publication Date August 2008
Publisher Datamonitor
Product Type Report
Pages 48
ISBN Number not applicable
Product Code DAT1099
|
|
|
Summary
Introduction
ViroPharma focuses on the development and commercialization of medicines to address diseases associated with hospital settings, transplant medicine and gastroenterology.
Scope
- Contains corporate strategy, value chain presence and SWOT Analysis
- Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
- Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
The company's total revenues increased at a CAGR of 134% during 2002-2006, from $6 million to $167 million. The company's biggest contributor to revenue growth during 2002-2006 was product sales of Vancocin.
The company's biggest contributor to sales growth out to 2010 will continue to be Vancocin.However, revenues from Vancocin are expected to increase only at a CAGR of 1%, from $167 million in 2006 to $175 million in 2010. This could be attributable to generic competition for Vancocin, whose patent expired in 1996.
Reasons to Purchase
- Access all the important information and analysis on the company in a single report
- Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
- Gain access to company's adjusted five year financial data along with key ratios and market capitalization
|
Content
- Overview
- Catalyst
- Summary
- Company Structure
- Company Overview and Key Facts
- Business Description
- History
- Company Financials
- Stock Market Performance
- P&L
- Balance Sheet
- Cash Flow
- Products & Services
- Marketed Products
- Pipeline Products
- Historical Product Sales
- AC Forecast Product Sales
- Competitors and Strategic Business Relationships
- Key Competitors
- Key Suppliers
- Key Clients
- Shareholding Structure
- Strategy
- Company View
- Corporate Strategy
- SWOT Analysis
- Overview
- Strengths
- Weaknesses
- Opportunities
- Threats
- Value Chain Analysis
- Overview
- Discovery and Product Development
- Sales
- Scorecard
- Overview
- Scorecard Analysis
- Key Employees
- List of Key Employees
- Key Employee Biographies
- Financial and Operational Overview
- Financial and Operational Overview
- APPENDIX
- Ask the analyst
- Datamonitor consulting
- Disclaimer
- TABLE OF FIGURES
- Figure1: ViroPharma- Operating Revenue/Cost Analysis, 2003-07 ($ Mn)
- Figure2: ViroPharma- Key Strategic Products Revenues, 2007-11 ($ Mn)
- TABLE OF TABLES
- Table 1: ViroPharma- Key Facts
- Table 2: ViroPharma- Year-End Share Price and Market Capitalization, 2003-07 ($)
- Table 3: ViroPharma- Key Events Impacting Share Price Performance, 2003-07
- Table 4: ViroPharma- Operating Revenue/Cost Analysis, 2003-07 ($ Mn)
- Table 5: ViroPharma- Operating Cost Ratio Analysis, 2003-07 (% of total revenues)
- Table 6: ViroPharma- Balance Sheet, 2003-07 ($ Mn)
- Table 7: ViroPharma- Cash Flow, 2003-07 ($ Mn)
- Table 8: ViroPharma- Marketed Products
- Table 9: ViroPharma- In-house Pipeline Products
- Table 10: ViroPharma- Historical Product Sales, 2003-07 ($ Mn)
- Table 11: ViroPharma- Forecast Sales, 2007-11 ($ Mn)
- Table 12: ViroPharma- Key Competitors
- Table 13: ViroPharma- Key Suppliers
- Table 14: ViroPharma- Key Clients
- Table 15: ViroPharma- Key Shareholders
- Table 16: ViroPharma- SWOT Analysis Summary
- Table 17: ViroPharma- Value Chain Analysis
- Table 18: ViroPharma- Scorecard
- Table 19: ViroPharma- Key Employees
- Table 20: ViroPharma - Financial and Operational Overview
|
|
|
